Komori
Other Disclosures4583Chiome Bioscience Inc.Pharmaceuticals

Notice of a Research Paper on Drug Discovery Using Our Antibodies

Results from joint research by our company and the National Institute of Infectious Diseases have been published in the academic journal Protein Science. The study showed that using anti-idiotypic antibodies as influenza vaccine antigens can induce antibodies reactive to multiple virus types in animals.

Worth reading
52Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Announced details

Influenza vaccine antigen design using anti-idiotypic antibodies
Applicable field (uses covered by this announcement)

Influenza vaccines, vaccine antigen design for readily mutating viruses, drug discovery research

What the company reported numerically
Quantitative Effects

Antibodies broadly reactive to multiple types of influenza virus were induced in the vaccinated animals. The figures are not disclosed.

Relationship between the counterparty and the company
Chiome Bioscience Inc.4583
Relationship with the Company

Joint research relationship.

CounterpartyDepartment of Infectious Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security (Director: Suzuki Tadaki (鈴木忠樹))

The Department of Infectious Pathology of the National Institute of Infectious Diseases, which is part of the Japan Institute for Health Security. The department director named in the paper is Suzuki Tadaki (鈴木忠樹). Other information on its location, representative, capital and year of establishment is not disclosed.

Registration number and expiry date

DOI: 10.1002/pro.70795 (identifier for the published paper; validity period not disclosed)

Impact on Business Performance

No information on the impact on financial results: Not disclosed.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Protein Science, paper title: “Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes”

Announced details
ItemDetails
Names of Products / Services CoveredInfluenza vaccine antigen design using anti-idiotypic antibodies
CounterpartyDepartment of Infectious Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security (Director: Suzuki Tadaki (鈴木忠樹))
Counterparty overviewThe Department of Infectious Pathology of the National Institute of Infectious Diseases, which is part of the Japan Institute for Health Security. The department director named in the paper is Suzuki Tadaki (鈴木忠樹). Other information on its location, representative, capital and year of establishment is not disclosed.
Relationship with the CompanyJoint research relationship.
Applicable areaInfluenza vaccines, vaccine antigen design for readily mutating viruses, drug discovery research
Registration number and expiry dateDOI: 10.1002/pro.70795 (identifier for the published paper; validity period not disclosed)
Quantitative EffectsAntibodies broadly reactive to multiple types of influenza virus were induced in the vaccinated animals. The figures are not disclosed.
Impact on Business PerformanceNo information on the impact on financial results: Not disclosed.
SourceProtein Science, paper title: “Anti-idiotypic antibodies as molecular mimics of conserved influenza hemagglutinin epitopes”
Items this document does not state (9)
Contract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyLocationLocation scaleUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Because a joint study with the National Institute of Infectious Diseases, Japan Institute for Health Security, examined a new approach to designing vaccine antigens that can provide broad coverage against influenza viruses, which readily mutate.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of a Research Paper on Drug Discovery Using Our Antibodies | Chiome Bioscience Inc. (4583) timely disclosure | Komori